Tracers / [177Lu]Lu-AKIR001
[177Lu]Lu-AKIR001
Also written as [Lu-177]Lu-AKIR001
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- phase 1 clinical trial
- Syntheses indexed
- 2
What it is
- Compound class
- CD44v6-targeted antibody conjugated with DOTA chelator, radiolabeled with Lu-177
- Target / mechanism
- CD44v6-targeted antibody radiotherapeutic PMID 41198237
- Clinical application
- CD44v6-positive solid cancers, phase 1 clinical trial PMID 41198237
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | AKIR001 antibody conjugated with p-SCN-Bn-DOTA | 42707719 2026 Theranostics [161Tb]TbCl3 was mixed with AKIR001 (10.4 µg/µl in a phosphate buffer with 0.04% polysorbate 80 (PS80), pH 6.5). |
| Manual synthesis | — | — | ≥99% | — | AKIR001 antibody SciLifeLab, Absolute Antibody, or Genscript Probio | 41198237 2026 J Nucl Med 177Lu-labeling involved incubating 50–400 µg of antibody with 15–130 MBq of 177Lu at 37 °C (≥99% yield) — ≥99% yield |
Need this precursor?We can point you to suppliers for [177Lu]Lu-AKIR001, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42707719: 'AKIR001 antibody conjugated with p-SCN-Bn-DOTA'. Stage set/updated at stage 23 from PMID 41198237: 'A phase 1 clinical trial of [177Lu]Lu-AKIR001for CD44v6-positive solid cancers (NCT06639191) is currently recruiting patients.'.